Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 7/20 | 0.44 |
| ▸ | GABRD | O14764 | 7/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.44 |
| ▸ | GABRE | P78334 | 7/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528175 | 0.95 | TNKS (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15528081 | 0.94 | POLB (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15528093 | 0.88 | POLB (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15528064 | 0.82 | CA1 (0.49) | ASAH1PTPN1ABCG2ABCB1CA1 | |
| SCHEMBL15528285 | 0.79 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8932 | 0.79 | GABRP (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15528157 | 0.77 | PIK3CD (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16457581 | 0.77 | PIK3CD (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9273 | 0.77 | GABRP (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8856 | 0.77 | GABRA1 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914343-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG Therapeutics Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2870157-A1 | SELECTIVE PI3K DELTA INHIBITORS | Rhizen Pharmaceuticals S.A. (CH) | 2015-05-13 | — | — | EP | disclosed |
| EP-2844647-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | Rhizen Pharmaceuticals S.A. (CH) | 2015-03-11 | — | — | EP | disclosed |
| WO-2014071125-A1 | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 KINASE SELECTIVE INHIBITOR | TG THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014006572-A1 | SELECTIVE PI3K DELTA INHIBITORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013164801-A1 | PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS | RHIZEN PHARMACEUTICALS SA (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | SYNGENE LIMITED (AU) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143565-A1 | Methods for the Synthesis of Two or More Dicarba Bridges in Organic Compounds | OTC, NBAS, IDH2 | GABRP 2716/4885GABRD 2470/4885GABRA1 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.